Please assess the completion status of the following clinical trial:

Trial Title: Micra Atrial TRacking Using A Ventricular AccELerometer 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has been implanted with a Micra TPS (Model MC1VR01) with remaining device longevity of 6 years or more or is expected to be implanted with a Micra TPS.~* Subject has history of AV block\*~* Subject is ≥ 18 years old and as per required local law.~* Subject (and/or witness as applicable per local regulations) provides signed and dated authorization and/or consent per institution and local requirements.~* Subject is willing and able to comply with the protocol. \*This includes subjects with normal sinus function and persistent 3rd degree AV block and subjects with other forms of AV block.~Exclusion Criteria:~* Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic Clinical Research Specialist.~* Subject is pregnant (if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to MARVEL 2 study procedures).~* Subject meets any exclusion criteria required by local law (age or other).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MARVEL 2 Algorithm Monitor Mode, Then MARVEL 2 Adaptive Mode (Type: EXPERIMENTAL): Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.

Based on this trial design, predict the completion outcome and termination type (if applicable).